On this episode of Wellness Unmasked, Dr. Nicole Saphier breaks down a major new development out of the White House: an executive order aimed at accelerating research into psychedelic therapies for mental health.

What does this mean for patients struggling with treatment-resistant depression, PTSD, and addiction? And could substances like psilocybin, MDMA, and ibogaine represent the next frontier in medicine—or a risky leap too far?

Dr. Saphier explores the science behind how these compounds interact with key brain systems like serotonin, dopamine, and opioid receptors, why traditional treatments often fall short, and what the data really says about effectiveness and risk. From promising clinical results to serious safety concerns—including cardiac risks and long-term psychological effects—this episode separates hype from reality.

Plus, a closer look at how the new policy could fast-track access for veterans and others battling severe mental illness, and why caution is still critical as research evolves.